Effects of two different doses of zinc sulfate on serum troponin I 3 enzyme level and cardiac malondialdehyde contents in mitoxantrone-induced cardiotoxicity in rats

Abstract EN

Mitoxantrone antineoplastic drugs used in the treatment cancers.

The mitoxantrone' may cause cardiotoxicity which is irreversible and dose-dependent.

Zinc is regarded as a necessary element for cell division and the production of DNA and protein; furthermore, it has a main role in alleviating cardiovascular diseases; and may have protective outcomes in coronary artery disease.

The current research is designed to investigate the effects of two different doses of zinc sulfate on mitoxantrone-induced cardiotoxicity in rats.

Forty-eight (48) adult Albino rats of both sexes were utilized in this study; the animals were randomly classified into six groups of 8 animals each.

Group I: Rats were received distilled water (negative control).

Group II: Orally-administered zinc sulfate (15mg/kg/day) Group III: orally-administered zinc sulfate (30mg/kg/day) Group IV: Rats Intraperitoneally injected with a mitoxantrone at a dose of (2.

5 mg/kg) to reach total cumulative dose of 7.

5 mg/kg on day 20 (positive control).

Group V: Orally-administered zinc sulfate at a dose (15mg/kg/day) and an intraperitoneal injection of mitoxantrone at a dose (2.

5 mg/kg) was administered to reach the total cumulative dose of 7.

5 mg/kg on day 20.

Group VI: Orally-administered zinc sulfate at a dose (30 mg/kg/day), and an intraperitoneal injection of mitoxantrone at a dose (2.

5 mg/kg) to reach the total cumulative dose of 7.

5 mg/kg on day 20.

Forty-eight (48) hours after the end of treatment duration (i.

e.

at day 22 nd), each animal was euthanized by diethyl ether and ketamine.

Then, after cervical dislocation, blood was obtained by cardiac puncture and then serum was prepared to estimate troponin I 3 enzyme levels, and the heart of each animal was excised for homogenate preparation to estimate of malondialdehyde contents.

It was found that oral administration of zinc sulfate [(15mg/kg/day with total cumulative dose (7.

5 mg/kg) of MTXN] (Group V), resulted in a non-significant (P>0.

05) differences in both serum level of troponin I 3 enzyme, and malondialdehyde (MDA) contents in heart tissue homogenate compared to the corresponding level and content in group of rats IP injected with total cumulative dose of 7.

5 mg/kg of MTXN (Group IV).

Moreover, there were significant reductions (P<0.

05) in serum level of troponin I 3 of rats orally-administered zinc sulfate [(30 mg/kg/day) with total cumulative dose (7.

5mg/kg) of MTXN] (Group VI) compared to the corresponding enzyme levels in serum of -Group IV rats that IP injected with total cumulative dose of 7.

5mg/kg of MTXN and -Group V rats that orally-administered zinc sulfate [(15mg/kg/day with total cumulative dose (7.

5 mg/kg) of MTXN].

Furthermore, there were significant reductions (P<0.

05) in MDA contents in heart tissue homogenate of Group VI rats compared to the corresponding contents in heart tissue homogenate of Group IV rats.

According to above results it can be concluded that zinc sulfate at a dose of (30 mg/kg/day) (in Group VI rats) diminished the cardiotoxicity induced by mitoxantrone as indicated by the reduction of serum troponin I 3 enzyme level but non-significant difference in lipid peroxidation marker (malondialdehyde) compared to (15 mg/kg/day) (in Group V rats).